Methods for treatment of autism

• US 9,442,092 B2
• Filed: 06/19/2012
• Issued: 09/13/2016
• Est. Priority Date: 06/20/2011
• Status: Active Grant

• Current Assignee: Kerry Lane
• Original Assignee: Kerry Lane
• Inventors: Lane, Kerry
• Primary Examiner(s): Chernyshev, Olga N
• Application Number:
  US14/127,493
• Publication Number:
  US 20140112940A1
• Time in Patent Office: 1,547 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/4076 Diagnosing or monitoring particular conditions of the nervous system A61B5/4821, A61B5/4824 take precedence
• CPC Class Codes: A61B 5/4082 Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
• CPC Class Codes: A61B 5/4088 Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
• CPC Class Codes: G01N 15/00 Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials identification of microorganisms C12Q
• CPC Class Codes: G01N 2333/37 from fungi
• CPC Class Codes: G01N 2800/28 Neurological disorders
• CPC Class Codes: G01N 2800/368 Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The current invention is directed towards a rapid, reproducible test for the fungal virulence factors and associated affected compounds so that patients at risk for autism, cerebral palsy and other human diseases can be quickly identified, treated and possibly prevented. This includes a multitude of test protocols for both the mycotoxin gliotoxin and its relationship with glutathione—and relates the two molecules by a novel paradigm known as the Glutathione-Gliotoxin Index—(GGI) or Disease-Disorder Susceptibility Index—D/DSI, which indicates the Autism Susceptibility Index—(ASI). One testing device and protocol includes a cellular phone application with modification to test for susceptibility to autism and other disease states. Of particular relevance for autism is the role of glutathione depletion by gliotoxin, then by the anti-pyretic acetaminophen in the peri-vaccination period, which each result in oxidative stress and metal intoxication, by disrupting the metallothionein system, amongst other biochemical pathways and numerous enzyme systems.

Claims

1. A method, comprising:

(a) measuring the level of glutathione in its reduced or oxidized state, or total glutathione in a sample from a subject;

(b) measuring the level of gliotoxin in a sample from the subject;

(c) administering to the subject, having below normal glutathione and toxicologically significant gliotoxin levels in the sample from the subject, one or more of antioxidants, anti-fungal and or fungistatic compounds, N-acetyl-cysteine, glutathione, selenium-adenosyl methionine (SAM), N-chlorotaurine to increase a ratio of the level of glutathione to the level of gliotoxin in the subject.

2. The method of claim 1, further comprising monitoring the subject by periodically calculating the ratio of the level of glutathione to the level of gliotoxin, and communicating the ratio to a health care practitioner.

3. The method of claim 1, further comprising measuring the levels of glutathione and gliotoxin independently or concurrently using a method that is:

optical radiation detection, high-pressure liquid chromatography (HPLC), reversed-phase liquid chromatography and HPLC, RP-HPLC/UV detection, thin-layer chromatography, radioimmunoas say (RIA), antibody-linked RIA, ELISA, spectro-photometry, mass spectroscopy—

MS, tandem MS, ES-MS, infrared spectroscopy, raman spectroscopy, lyophilized ligand-receptor complexes for assays and sensors, packed-flow cell fluorescence liquid chromatography (PFCFLC), antibody-linked immunoassay, adsorption chromatography, immuno-affinity chromatography, supercritical fluid extraction, bio-luminescence, chemical luminescence, NMR, isotopic S35 labeled quantification, radioactive scintillation, chiro-optical spectroscopy, polarimetry, optical rotatory dispersion, circular dichroism, circularly polarized luminescence, the use of Ellman'"'"'s Reagent followed by UV-vis measurement, or any combination thereof.

4. The method of claim 1, wherein the sample is any bodily fluid, tissue hair, stool, urine, cerebrospinal fluid—

CSF, expired respiratory gas, or flatulence.

5. The method of claim 1, wherein the samples are erythrocytes.

6. The method of claim 2, wherein the communicating is performed via a portable communication device, scanner, electronic handheld device, cellular phone.

7. The method of claim 1, wherein the administering comprises administering to the subject one or more of N-acetyl-cysteine and glutathione by either intranasal or rectal administration.

8. The method of claim 1, wherein the glutathione level in the sample from the subject is less than about 30% of normal or oxidized.

9. The method of claim 1, wherein the gliotoxin level in the sample from the subject is more than about 20 nanograms/ml.

10. The method of claim 1, wherein the subject is being treated for autism, cerebral palsy, or Alzheimer'"'"'s disease.

11. The method of claim 1, further comprising periodically monitoring the ratio of glutathione level to gliotoxin level in the subject when the level of glutathione in the sample is below normal.

12. A method, comprising:

(a) measuring the level of glutathione in a sample from a subject;

(b) measuring the level of gliotoxin in a sample from the subject;

(c) if the level of glutathione in the sample from the subject is below normal and the level of gliotoxin in the sample is toxicologically significant, treating the subject to increase a ratio of the level of glutathione to the level of gliotoxin in the subject,

wherein the treating comprises administering to the subject one or more of anti-oxidants, anti-fungal and or fungistatic compounds, N-acetyl-cysteine, glutathione, selenium-adenosyl methionine (SAM), N-chlorotaurine by either intranasal or rectal administration.

13. The method of claim 12, wherein the glutathione is in its reduced state.

14. The method of claim 12, wherein the glutathione is in its oxidized state.

15. The method of claim 12, wherein the glutathione is its reduced or oxidized state or total glutathione, which is the sum of the oxidized and reduced glutathione.

16. The method of claim 12, further comprising monitoring the subject by periodically calculating the ratio of the level of glutathione to the level of gliotoxin, and communicating, via a portable communication device, scanner, electronic handheld device, or cellular phone, the ratio to a health practitioner.

17. The method of claim 12, wherein the subject is being treated for autism, cerebral palsy or Alzheimer'"'"'s disease.

18. The method of claim 12, further comprising periodically monitoring the ratio of glutathione level to gliotoxin level in the subject when the level of glutathione in the sample is below normal.

19. The method of claim 12, wherein the glutathione level in the sample from the subject is less than about 30% of normal or oxidized.

20. The method of claim 12, wherein the gliotoxin level in the sample from the subject is more than about 20 nanograms/ml.